It comes as immediate-release and extended-release oral tablets, and extended-release oral capsules. It also comes in an injectable form that’s only given by a healthcare provider. Metoprolol oral tablets are available as the brand-name drugs Lopressor and Toprol XL. Generic drugs usually cost less than the brand-name versions. In some cases, they may not be available in all strengths or forms as the brand-name drugs. The two brand-name forms of metoprolol (as well as the different generic forms) are different versions of the medication. They’re both metoprolol, but they contain different salt forms. The different salt forms enable the drugs to be used to treat different conditions. Metoprolol succinate is an extended-release version of metoprolol, so it remains in your bloodstream for a longer time. Pill with imprint m 200 is White, Elliptical / Oval and has been identified as Metoprolol Succinate Extended-Release 200 mg. Metoprolol is used in the treatment of high blood pressure; atrial fibrillation; supraventricular tachycardia; angina; tapering regimen (and more), and belongs to the drug class cardioselective beta blockers. Metoprolol 200 mg is not a controlled substance under the Controlled Substances Act (CSA). Lasix chf Metformin aspirin Capsule, Extended Release; Tablet, Extended Release; Tablet; Powder for Solution. However, the dose is usually not more than 200 mg per day. Metoprolol Lopressor ® and Toprol-XL ® comes in the form of immediate-release or extended-release tablets. However, 200 mg metoprolol tablets are only available in the extended-release form. A healthcare provider may prescribe metoprolol to treat several conditions related to the heart and blood vessels. Find patient medical information for Metoprolol Succinate Oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. This is an open Label, randomized, two-period, two-treatment, two-sequence, crossover, balanced, single dose pivotal study. A positive hepatitis screen (includes subtypes B & C). A positive test result for HIV antibody and / or syphilis (RPR/VDRL). Volunteers who have donated blood (1 unit or 450 m L) within 90 days prior to the initial dose of the study drug or have blood loss, excluding volume drawn at screening for this study, (≤100 m L within 30 days; ≤200 m L within 60 days; 200 m L within 90 days) prior to initial dose of study drug. History of difficulty in swallowing, or of any gastrointestinal disease which could affect drug absorption. Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fed condition in healthy adult human subjects. Please see the identifier information above for retrieving further details from the government database. Full Title of Study: “An Open Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Crossover, Balanced, Single Dose Oral Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 200 mg of Ipca Laboratories Limited, India and ‘Toprol-XL®’ (Metoprolol Succinate) Extended Release Tablets 200 mg of Astrazeneca LP, USA In Healthy Adult Human Subjects Under Fed Conditions” Objective of this pivotal study was to assess the bioequivalence between Test Product: Metoprolol Succinate 200 mg Ipca Laboratories Limited, India and the corresponding Reference Product: TOPROL-XL® (Metoprolol Succinate) extended release Tablets 200 mg of Astrazenica LP, USA under fed condition in healthy adult human subjects in a randomized crossover study. BMI: 18.5 to 24.9 weight in kg/(height in meter)2 both inclusive; 4. Use of any hormone replacement therapy within 3 months prior to study medication dosing. A depot injection or implant of any drug within 3 months prior to administration of study medication. Use of enzyme-modifying drugs within 30 days prior to receiving the first dose of study medication. History or evidence of drug dependence or of alcoholism or of moderate alcohol use. Smokers who smoke 10 or more cigarettes per day or 20 or more biddies per day or those who cannot refrain from smoking during the study period. History of difficulty with donating blood or difficulty in accessibility of veins. https://trialbulletin.com/lib/entry/ct-01884909At Trial Bulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. The study was conducted with 48 healthy adult subjects. Sex: Males and/or non-pregnant, non-lactating females. Able to communicate effectively with study personnel and willingness to follow the protocol requirements as evidenced by written informed consent. Able to give written informed consent to participate in the study. All volunteers must be judged by the principal or co-investigator or physician as normal and healthy during a pre-study safety assessment performed within 21 days of the first dose of study medication which will include: 1. In each study period, a single 200 mg dose of either test or reference was administered to the subjects as per the randomization schedule in each study period with about 240 m L of water at ambient temperature in sitting position. History of allergic responses to Metoprolol Succinate or other related drugs, or any of its formulation ingredients. Have significant diseases or clinically significant abnormal findings during screening, [medical history, physical examination, laboratory evaluations, ECG, chest X-ray recording, obstetrics and gynecological history and examination along with PAP smear (for female volunteers) & transvaginal ultrasonography (for female volunteers)]. Any disease or condition which might compromise the haemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system, diabetes, psychosis or any other body system. The duration of the clinical phase was approximately 11 days including washout period of at least 7 days between administrations of study drug in each study period. Any food allergy, intolerance, restriction or special diet that, in the opinion of the Principal Investigator or Co-Investigator, could contraindicate the volunteer's participation in this study. Volunteers who have received a known investigational drug within five elimination half life of the administered drug prior to the initial dose of study drug or who have participated in a clinical drug study or bioequivalence study within 90 days prior to the initial dose of study drug, whichever is greater. Found positive in urine test for drugs of abuse done before check-in of period I. ) comes in the form of immediate-release or extended-release tablets. However, 200 mg metoprolol tablets are only available in the extended-release form. A healthcare provider may prescribe metoprolol to treat several conditions related to the heart and blood vessels. However, your metoprolol dosage will be based on several factors, such as your age, the form of metoprolol, the medical condition being treated, other medical conditions you may have, and other medications you are currently taking. For example, your healthcare provider may prescribe the 200 mg tablets once or twice daily to treat conditions such as high blood pressure or angina. Based on the response and/or side effects, the dosage of metoprolol may be increased or decreased until the optimal dose is determined. Some of the possible side effects of metoprolol include tiredness, dizziness, and diarrhea.(Click Metoprolol Dosing for more information on when your healthcare provider may prescribe metoprolol. Metoprolol 200 mg tablet Metoprolol Davis's Drug Guide, Metoprolol 200 mg Tablets - Heart Disease Home Page Fluconazole headacheCipro tendonPropecia alcoholAzithromycin dose for chlamydiaDoxycycline urethritis Metoprolol oral tablet is a prescription medication used to treat high blood pressure, chest pain, and heart stress after a heart attack. It's a drug called a beta-blocker. or up to 200 mg per. Metoprolol, Oral Tablet - Healthline. Metoprolol Succinate Oral Uses, Side Effects, Interactions.. Tablets 25 mg, 50 mg, 100 mg, and 200 mg. M 200 Metoprolol Succinate Extended-Release 200 mg Pill with imprint m 200 is White, Elliptical / Oval and has been identified as Metoprolol Succinate Extended-Release 200 mg. It is supplied by Par Pharmaceutical Inc. Objective of this pivotal study was to assess the bioequivalence between Test Product Metoprolol Succinate 200 mg Ipca Laboratories Limited, India and the corresponding Reference Product TOPROL-XL® Metoprolol Succinate extended release Tablets 200 mg of Astrazenica LP. Руб. Состав МЕТОПРОЛОЛА ZOT STADA таблетки Ретард 200 мг. 1 табл. содержит. Активные ингредиенты. 156.17 мг метопролола. 200 мг метопролола тартрата. Вспомогательные вещества. Магния стеарат.